You are here

Article Text

Article menu
Download PDFPDF
Economics
An intranasal influenza vaccine for the prevention of influenza in healthy children was cost effective

https://doi.org/10.1136/ebm.7.2.63

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    (2001) Pediatrics 108, e24. Luce BR, Zangwill KM, Palmer CS. , et al. . Cost-effectiveness analysis of an intranasal influenza vaccine for the prevention of influenza in healthy children.. Aug;. :. ..
    OpenUrlAbstract/FREE Full Text

    
 
 QUESTION: In healthy children, is an intranasal influenza vaccine for the prevention of influenza cost effective?

    Design

    Randomised {allocation concealed*}†, blinded {patients, healthcare providers, data collectors, judicial assessors of outcomes, data analysts, data safety and monitoring committee, and manuscript writers}†,* placebo controlled trial with 2 years of follow up.

    Setting

    University medical centres in 7 cities in the USA.

    Patients

    2960 healthy children who were 15 to 71 months of age (mean age 42 mo, 52% girls). Follow up was > 97%.

    Intervention

    Children were allocated to receive 1 or 2 doses of a live, attenuated, trivalent, intranasal influenza vaccine (n=1987) or placebo (n=973) for the 1996–1997 and 1997–1998 seasons.

    Main cost and outcome measures

    Cost per febrile influenza-like illness (ILI) day avoided. A break-even analysis was also done to calculate the vaccine plus administration cost below which its …

    View Full Text

    Footnotes

    • ↵* See glossary.

    • ↵† Information provided by author.

    • Sources of funding: Aviron and National Institutes of Health.

    • For correspondence: Dr B R Luce, MEDTAP International, Bethesda, MD, USA. luce{at}medtap.com.